Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$9.77 - $21.47 $2.52 Million - $5.54 Million
257,963 Added 272.31%
352,695 $5.19 Million
Q4 2023

Feb 13, 2024

BUY
$4.48 - $10.11 $424,399 - $957,740
94,732 New
94,732 $911,000
Q2 2022

Aug 12, 2022

SELL
$2.25 - $9.99 $467,196 - $2.07 Million
-207,643 Closed
0 $0
Q1 2022

May 13, 2022

BUY
$8.12 - $16.9 $291,215 - $606,101
35,864 Added 20.88%
207,643 $1.83 Million
Q4 2021

Feb 10, 2022

BUY
$15.91 - $21.88 $1.08 Million - $1.48 Million
67,848 Added 65.28%
171,779 $2.76 Million
Q3 2021

Nov 10, 2021

SELL
$19.74 - $28.7 $362,426 - $526,932
-18,360 Reduced 15.01%
103,931 $2.18 Million
Q2 2021

Aug 10, 2021

BUY
$20.49 - $35.63 $244,281 - $424,780
11,922 Added 10.8%
122,291 $3.29 Million
Q1 2021

May 10, 2021

BUY
$18.99 - $33.2 $1.67 Million - $2.92 Million
87,893 Added 391.05%
110,369 $3.52 Million
Q4 2020

Feb 10, 2021

SELL
$19.41 - $26.0 $580,999 - $778,258
-29,933 Reduced 57.11%
22,476 $514,000
Q3 2020

Nov 13, 2020

BUY
$24.69 - $31.6 $1.04 Million - $1.34 Million
42,294 Added 418.13%
52,409 $1.32 Million
Q2 2020

Aug 07, 2020

BUY
$5.2 - $29.12 $52,598 - $294,548
10,115 New
10,115 $282,000
Q1 2020

May 15, 2020

SELL
$4.28 - $12.11 $213,811 - $604,967
-49,956 Closed
0 $0
Q4 2019

Feb 10, 2020

SELL
$7.95 - $12.27 $344,513 - $531,720
-43,335 Reduced 46.45%
49,956 $544,000
Q3 2019

Nov 14, 2019

SELL
$12.44 - $17.48 $617,359 - $867,479
-49,627 Reduced 34.72%
93,291 $1.19 Million
Q2 2019

Aug 09, 2019

BUY
$14.51 - $19.71 $1.35 Million - $1.84 Million
93,157 Added 187.21%
142,918 $2.43 Million
Q1 2019

May 15, 2019

BUY
$11.11 - $25.6 $552,844 - $1.27 Million
49,761 New
49,761 $895,000

Others Institutions Holding MGNX

About MACROGENICS INC


  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $200M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track This Portfolio

Track Rafferty Asset Management, LLC Portfolio

Follow Rafferty Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.